May be taken with or without food.
Administration
May be taken with or without food.
|
Contraindications
Severe hepatic impairment. Pregnancy. Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2).
|
Special Precautions
Patient with history of angioedema, volume and/or Na depletion, heart failure, bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy, ischaemic CV and cerebrovascular disease. Patient undergoing surgery. Black patients. Not recommended for use in patients with ascites due to cirrhosis or refractory ascites; primary hyperaldosteronism. Renal impairment and mild to moderate hepatic impairment. Children and elderly. Lactation. Patient Counselling This drug may occasionally cause dizziness or drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure (at baseline and periodically), renal function, and electrolytes (e.g. serum K). Assess for signs of angioedema.
|
Adverse Reactions
Significant: Renal failure (e.g. acute kidney injury), symptomatic hypotension (in volume- and/or Na-depleted patients), electrolyte imbalance (e.g. hyperkalaemia), angioedema.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Angina pectoris, palpitations.
Ear and labyrinth disorders: Tinnitus, vertigo.
Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Oedema, asthenia, fatigue.
Hepatobiliary disorders: Rarely, hepatitis.
Investigations: Increase in serum creatinine or blood urea.
Metabolism and nutrition disorders: Hypoglycaemia.
Musculoskeletal and connective tissue disorders: Back pain, arthralgia, myalgia; rarely, rhabdomyolysis.
Nervous system disorders: Dizziness, headache, migraine, paraesthesia.
Psychiatric disorders: Sleep disorders, depression.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Skin and subcutaneous tissue disorders: Urticaria, pruritus, rash.
Vascular disorders: Orthostatic hypotension, syncope.
|
Drug Interactions
May increase the risk of hypotension with TCAs, antipsychotics, baclofen, and amifostine. Concomitant use with fluconazole may increase the plasma concentration of losartan but decrease the plasma concentration of the active metabolite. Decreased plasma concentration with rifampicin. Increased serum K levels with K-sparing diuretics (e.g. amiloride, spironolactone, triamterene), K supplements, K-containing salt substitutes, or other drugs that may increase serum K (e.g. heparin, trimethoprim-containing products); not recommended for concomitant use. May increase serum lithium concentrations and toxicity. Concomitant use with NSAIDs (e.g. selective COX-2 inhibitors, aspirin, non-selective NSAIDs) may increase the risk of worsening of renal function (including possible acute renal failure) and may decrease the hypotensive effect of losartan.
|
CIMS Class
|
ATC Classification
C09CA01 - losartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.
|